The disease's greatest weapon is its silence.
Each year in Colombia, more than 16,000 men are diagnosed with prostate cancer, and for nearly a third of them, the diagnosis arrives too late — not because medicine failed them first, but because silence did. The disease speaks no early language the body can hear, and cultural habits of avoidance have long kept men from seeking the screenings that could catch it while it is still curable. Where wealthy nations see metastatic diagnoses in fewer than five of every hundred cases, Colombia sees thirty to forty, a gap that measures not only a healthcare disparity but a human one. The tools to close that distance exist; what remains is the harder work of changing how men understand their own bodies and their responsibility to them.
- Between 30 and 40 percent of Colombian prostate cancer patients arrive at diagnosis with metastatic disease — a rate up to eight times higher than in industrialized countries, signaling a systemic failure of prevention.
- The cancer's silence is its cruelest advantage: it produces no symptoms in early stages, and the urinary trouble men do notice usually signals benign aging, not malignancy — by the time they feel sick, the window for cure may have already closed.
- Cultural resistance to the digital rectal exam and a broader reluctance among men to engage in preventive care mean that many only reach a clinic because a spouse or family member insisted, not out of personal conviction.
- Advanced robotic surgery and new biopsy techniques are improving outcomes for those caught early, while a generation of targeted therapies has meaningfully extended survival even for men with widespread disease.
- Prostate cancer already consumes roughly a quarter of Colombia's high-cost disease budget — a financial pressure that will only grow if late-stage diagnoses remain the norm rather than the exception.
In Colombia, a man feels fine and skips his checkup. A year passes, then another. By the time something feels wrong, the cancer has already spread — and his odds have narrowed considerably. This is not an isolated story. It is the experience of 30 to 40 percent of the more than 16,000 Colombians diagnosed with prostate cancer each year, a proportion that dwarfs the under-5 percent metastatic rate seen in wealthier nations.
Dr. Juan Camilo Ospina, head of urology at Clínica del Country and Clínica La Colina, describes the disease's central deception: it produces no early symptoms. The prostate sits deep in the body, and tumors can grow silently for years. Men typically wait for urinary difficulty before seeing a doctor — but that symptom almost always points to benign enlargement, not cancer. The confusion costs lives. Cultural resistance to the digital rectal exam, a three-to-four-second assessment that can catch what blood tests miss, has historically compounded the problem, though attitudes are slowly shifting. Men with a family history of prostate or breast cancer, and men of African descent, face elevated risk and should begin screening at 45.
Detection relies on three steps: a PSA blood test, a digital rectal exam, and MRI when findings warrant it. Ultrasound, despite common belief, cannot reliably identify prostate cancer. When surgery is needed, robotic systems like the Da Vinci Xi allow millimeter-precise removal while protecting the nerves governing erectile function and urinary control — the outcomes men fear most. A newer transperineal biopsy technique has also nearly eliminated infection risk while improving accuracy.
For those who arrive with advanced disease, oncologist Dr. Juan Carlos Velásquez points to a transformed landscape. Targeted therapies and second-generation hormone blockers have rewritten survival curves over the past 15 years, allowing men with metastatic cancer to live for years with meaningful quality of life. Multidisciplinary teams now tailor treatment from active surveillance to systemic therapy depending on each case.
The paradox holds: early detection is the most effective tool available, yet thousands continue to arrive too late. The silence of the disease, layered over fear and cultural hesitation, makes prevention — the simplest intervention — the hardest one to deliver.
In Colombia, a man waits too long. He feels fine, so he skips his annual checkup. A year passes, then another. By the time he notices something wrong—trouble urinating, maybe—the cancer has already spread beyond his prostate. He arrives at the hospital with metastatic disease, and his chances of survival have narrowed considerably.
This scenario plays out for between 30 and 40 percent of Colombian men diagnosed with prostate cancer each year, according to doctors at Clínica del Country and Clínica La Colina. More than 16,000 Colombians receive a prostate cancer diagnosis annually, yet the proportion arriving with advanced disease far exceeds what happens in wealthy nations, where metastatic cases at diagnosis represent less than 5 percent of the total. The gap is stark and troubling, and it reflects a fundamental challenge in Colombian medicine: the disease advances silently, and cultural barriers keep men from seeking prevention.
Dr. Juan Camilo Ospina, head of urology at both clinics, frames the problem plainly. Prostate cancer rarely announces itself in early stages. Men feel nothing. The gland sits deep in the body, and tumors can grow for years without producing a single symptom. This silence is the disease's greatest weapon. Many men wait for urinary trouble before consulting a doctor, but here lies a dangerous misunderstanding: difficulty urinating usually signals benign enlargement of the prostate—a normal part of aging—not cancer. By the time a man feels sick enough to seek help, the malignancy may have already escaped the gland and seeded elsewhere in his body.
Cultural resistance compounds the medical reality. Some men have historically refused the digital rectal exam, a quick assessment that takes three to four seconds and can reveal abnormalities a blood test might miss. Ospina notes this attitude is shifting, though many men still arrive at the clinic only because a wife or family member pushed them to go, not because they view preventive screening as part of their own responsibility. Certain populations require heightened vigilance: men with a family history of prostate or breast cancer, and men of African descent, who face higher disease incidence and should begin screening at 45 rather than 50.
The detection protocol rests on three pillars. First is the PSA test—prostate-specific antigen measured in blood—the primary warning signal. Second is the digital rectal exam performed by a urologist, which can catch changes other methods miss. Third is magnetic resonance imaging, ordered when PSA or physical findings raise suspicion. Only when MRI shows concerning findings does a biopsy follow. Ultrasound, despite what many patients believe, cannot reliably detect prostate cancer.
The cost of late detection extends beyond individual suffering. Ospina reports that roughly 25 percent of Colombia's resources for high-cost diseases go to prostate cancer treatment. Managing advanced disease strains the national healthcare economy severely. Yet innovation offers some counterweight. Both clinics have invested in robotic surgery—the Da Vinci Xi system—which allows surgeons to remove the prostate with millimeter precision while preserving nerves critical to erectile function and urinary control, the two complications men fear most. A newer biopsy technique, transperineal fusion biopsy, accesses the prostate through the perineum rather than the rectum, virtually eliminating the risk of serious infection while improving accuracy in spotting suspicious lesions.
For the thousands who arrive with metastatic disease anyway, Dr. Juan Carlos Velásquez, head of clinical oncology, offers a measure of hope. Therapeutic advances over the past 15 years have transformed the outlook for advanced prostate cancer dramatically. Targeted therapies, second-generation hormone blockers, and systemic treatments have rewritten survival curves. Men with widespread disease can now live for years with good quality of life—a reality unimaginable a decade ago. Treatment decisions flow from a multidisciplinary team of urologists, oncologists, and pathologists, tailoring each approach to the individual case, from active surveillance for low-risk tumors to systemic therapy for advanced disease.
The paradox is this: early detection remains the most effective strategy, yet thousands continue to arrive too late. The disease's silence, combined with fear and cultural hesitation, means that prevention—the simplest intervention—remains the hardest to achieve.
Citações Notáveis
The greatest danger of prostate cancer is its silence.— Dr. Juan Camilo Ospina, head of urology
Patients with advanced disease today can live many years with excellent quality of life thanks to targeted therapies and new hormone blockers.— Dr. Juan Carlos Velásquez, head of clinical oncology
A Conversa do Hearth Outra perspectiva sobre a história
Why does prostate cancer spread so far before men know they have it?
Because it doesn't hurt. It doesn't announce itself. A man can have a growing tumor for years and feel completely fine. By the time his body sends a signal—trouble urinating—he's often already at an advanced stage.
But men get checkups for other things. Why not this?
Some do, but many don't. There's a cultural piece here—resistance to the digital rectal exam, embarrassment, the idea that if you feel okay, you don't need a doctor. And honestly, a lot of men just don't think about it until something hurts.
So the gap between Colombia and wealthy countries—that's not about access to treatment, it's about prevention?
Partly. But it's also about awareness and screening infrastructure. In countries with lower metastatic rates, men are getting PSA tests routinely. Here, that's not happening at the same scale.
What changes that?
Education, mainly. Men need to understand that waiting to feel sick is waiting too long. And doctors need to reach men who don't come in on their own—through family, through workplace programs, through making screening normal rather than something to fear.
If someone does arrive with advanced disease, is it a death sentence?
Not anymore. The treatments have changed dramatically in the last 15 years. Men with metastatic cancer can live for years now with decent quality of life. But they'd live longer and better if they'd caught it early.
So the real tragedy is preventable?
Yes. That's what makes this so urgent.